Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype…